ASF partners with AS father and advocate to celebrate global strides in Angelman syndrome research, patient care AURORA, Ill. (Feb. 15, 2019) – Today, in celebration of International Angelman Day on Feb. 15, the Angelman Syndrome Foundation (ASF) partnered with Angelman […]
Read more
Comprehensive Clinics Provide Unique Support for Individuals with Angelman Syndrome in Canada and Israel AURORA, Ill. (December 6, 2018) – The Angelman Syndrome Foundation (ASF) expands its Angelman Syndrome Clinic Network through collaboration with international partners: The Children’s Hospital of Eastern Ontario in Ottawa, Canada, and the Edmond and […]
Read more
On December 6, 2018, Ovid Therapeutics announced plans to move ahead with a single, pivotal Phase 3 trial of once-daily dosing of OV101 in pediatric patients with Angelman syndrome. This is based on its End-of-Phase 2 Meeting with the U.S. […]
Read more
Congratulations to Dr. Mark Zylka who has been recognized as a 2017 American Association for the Advancement of Science (AAAS) Fellow! The AAAS fellows date back to 1874 and have included such prestigious recipients as Thomas Edison and Margaret Mead. More recently, […]
Read moreWorld’s Largest Newborn Screening Study for Angelman, Prader-Willi, Fragile X and Dup15q Syndromes Launches Nonprofits co-fund feasibility study to test screening tool for 75,000 newborns for Angelman, Prader-Willi, Fragile X and Dup15q Syndromes AURORA, Ill., and WALNUT, Calif. (November 8, […]
Read more Additional Data and Analyses from the Phase 2 STARS Clinical Trial with OV101 Ovid Therapeutics Presents Additional Data and Analyses from the Phase 2 STARS Clinical Trial with OV101 for the Treatment of Angelman Syndrome at the 65th AACAP Annual Meeting […]
Read more
The First Comprehensive Clinic in Illinois Providing Support for Individuals with Angelman Syndrome (CHICAGO) – Rush University Medical Center and the Angelman Syndrome Foundation (ASF), a national nonprofit organization headquartered in Aurora, Ill., announced the official opening of the Angelman […]
Read more— OV101 achieved primary endpoint of safety and tolerability — — Robust and statistically significant improvement (p=0.0006) in the first prespecified efficacy endpoint(CGI-I) observed at 12 weeks of treatment in once-daily dose group compared to placebo — — STARS data […]
Read more
